María Miguélez González
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
María Miguélez González has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
Diego Muñoz Moreno
Department of Endocrinology, Hospital General Universitario Gregorio, Marañón, Madrid, Spain
5 shared publications- Alejandra Maricel Rivas Montenegro
Servicio de Endocrinología. Hospital General Universitario Gregorio Marañón, Madrid, España
4 shared publications - Laura González Fernández
Department of Endocrinology and Nutrition, Hospital General Universitario Gregorio Marañón, 28007 Madrid, Spain
4 shared publications - Noemi Brox-Torrecilla
Servicio de Endocrinología. Hospital General Universitario Gregorio Marañón, Madrid, España
4 shared publications - Elisa Fernández Fernández
Servicio de Endocrinología. Hospital General Universitario Gregorio Marañón, Madrid, España. logía. Hospital General Universitario Gregorio Marañón, Madrid, España
2 shared publications - Iker Miret Atxikallende
Servicio de Endocrinología. Hospital Universitario De Cruces, Bilbao, España
2 shared publications
Latest Publications
- 22 August 2025
- Published by Wiley in World Journal of Surgery
- Vol. 49 (10) , 2777-2781
Rapidly Growing Thyroid Masses in Adults: Urgent Diagnostic Challenges and Effective Management—Single‐Center Experience and Literature Review
- 22 August 2025
- Published by Wiley in World Journal of Surgery
- Vol. 49 (10) , 2777-2781
Rapidly Growing Thyroid Masses in Adults: Urgent Diagnostic Challenges and Effective Management—Single‐Center Experience and Literature Review
- Open Access
- 18 April 2025
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 27 (10) , 3849-3859
Oncological needs in transgender patients
Transgender people encounter unique health disparities in oncology. They face substantial barriers in accessing healthcare that are exaggerated by bias/discrimination from healthcare professionals and systems, and socio-economic marginalisation. This review explores the current landscape of cancer risk, screening and management in transgender individuals from a Spanish perspective. Nationwide data are lacking, but estimates from Madrid suggest that 22 per 100,000 individuals are transgender. The needs of the transgender individual for gender-affirming surgeries and gender-affirming hormone therapy may alter the individual’s oncological risk profile and likelihood of receiving appropriate screening, and when diagnosed with cancer may have to be balanced against treatment requirements (e.g., endocrine therapy for breast cancer). There remain unmet needs in the oncological care of the transgender patient. Concerted effort is required to address clinical research gaps, and reform healthcare education and policy, in order to develop inclusive clinical practices that enhance patient care and outcomes.
- 18 April 2025
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 27 (10) , 3849-3859
Open AccessOncological needs in transgender patients
Transgender people encounter unique health disparities in oncology. They face substantial barriers in accessing healthcare that are exaggerated by bias/discrimination from healthcare professionals and systems, and socio-economic marginalisation. This review explores the current landscape of cancer risk, screening and management in transgender individuals from a Spanish perspective. Nationwide data are lacking, but estimates from Madrid suggest that 22 per 100,000 individuals are transgender. The needs of the transgender individual for gender-affirming surgeries and gender-affirming hormone therapy may alter the individual’s oncological risk profile and likelihood of receiving appropriate screening, and when diagnosed with cancer may have to be balanced against treatment requirements (e.g., endocrine therapy for breast cancer). There remain unmet needs in the oncological care of the transgender patient. Concerted effort is required to address clinical research gaps, and reform healthcare education and policy, in order to develop inclusive clinical practices that enhance patient care and outcomes.
- 1 November 2024
- Published by Bentham Science Publishers Ltd. in Endocrine, Metabolic & Immune Disorders - Drug Targets
- Vol. 24 (14) , 1628-1639
Endocrine Adverse Events Related To Immune Checkpoint Inhibitor Treatment: Relationship Between Antibodies and Severity of Thyroid Dysfunction
Objective: The purpose of this study was to identify predictive and risk factors for the development of immune-related endocrinopathies and to analyze the incidence and characteristics of immune-related endocrinopathies in our population Design: A retrospective, single-centre cohort carried out at Gregorio Marañón Hospital between January 2018 -December 2019. Methods: A total of 163 patients were enrolled. In January 2018 and December 2019, we treated patients who underwent ICI treatment in the Medical Oncology Department of General University Hospital Gregorio Marañón, a tertiary care public hospital in Madrid, as part of an observational, retrospective, single-center cohort study. Results: Endocrinopathies were diagnosed in 19.5% of the patients (n = 32). The tumours with the highest incidence of endocrinopathies were non-small cell lung cancer (25,9%), kidney cell cancer (25%) and hepatocarcinoma (20%). Among the 32 patients who developed endocrinopathy, 18,8%, 19,13%, and 21,28% received anti-CTLA-4, anti-PD-1 and anti-PDL-1, respectively. Thyroid dysfunction was the most frequent endocrinopathy (12,8%). A higher percentage of patients with negative antiTPO and antiTG antibodies developed G1 hypothyroidism compared to patients with positive antibodies who developed a higher proportion of G2 hypothyroidism. The presence of an initial phase of thyrotoxicity was not related to greater severity. We observed longer progression-free survival in patients who developed thyroid dysfunction. Conclusion: Pre-existing antibodies were independently associated with endocrinopathies. Moreover, our study let us conclude that the presence of thyroid autoantibodies may be related to its severity. It is important to determine anti-thyroid antibodies prior to the start of immunotherapy as a risk factor for thyroid dysfunction, which in turn is a prognostic marker.
- 1 November 2024
- Published by Bentham Science Publishers Ltd. in Endocrine, Metabolic & Immune Disorders - Drug Targets
- Vol. 24 (14) , 1628-1639
Endocrine Adverse Events Related To Immune Checkpoint Inhibitor Treatment: Relationship Between Antibodies and Severity of Thyroid Dysfunction
Objective: The purpose of this study was to identify predictive and risk factors for the development of immune-related endocrinopathies and to analyze the incidence and characteristics of immune-related endocrinopathies in our population Design: A retrospective, single-centre cohort carried out at Gregorio Marañón Hospital between January 2018 -December 2019. Methods: A total of 163 patients were enrolled. In January 2018 and December 2019, we treated patients who underwent ICI treatment in the Medical Oncology Department of General University Hospital Gregorio Marañón, a tertiary care public hospital in Madrid, as part of an observational, retrospective, single-center cohort study. Results: Endocrinopathies were diagnosed in 19.5% of the patients (n = 32). The tumours with the highest incidence of endocrinopathies were non-small cell lung cancer (25,9%), kidney cell cancer (25%) and hepatocarcinoma (20%). Among the 32 patients who developed endocrinopathy, 18,8%, 19,13%, and 21,28% received anti-CTLA-4, anti-PD-1 and anti-PDL-1, respectively. Thyroid dysfunction was the most frequent endocrinopathy (12,8%). A higher percentage of patients with negative antiTPO and antiTG antibodies developed G1 hypothyroidism compared to patients with positive antibodies who developed a higher proportion of G2 hypothyroidism. The presence of an initial phase of thyrotoxicity was not related to greater severity. We observed longer progression-free survival in patients who developed thyroid dysfunction. Conclusion: Pre-existing antibodies were independently associated with endocrinopathies. Moreover, our study let us conclude that the presence of thyroid autoantibodies may be related to its severity. It is important to determine anti-thyroid antibodies prior to the start of immunotherapy as a risk factor for thyroid dysfunction, which in turn is a prognostic marker.
- 1 November 2021
- Published by Elsevier in Clinical Nutrition
- Vol. 41 (12) , 2940-2946
Nutritional management and clinical outcome of critically ill patients with COVID-19: A retrospective study in a tertiary hospital
- 1 November 2021
- Published by Elsevier in Clinical Nutrition
- Vol. 41 (12) , 2940-2946
Nutritional management and clinical outcome of critically ill patients with COVID-19: A retrospective study in a tertiary hospital